Andrew Saik's most recent trade in Arvinas Inc was a trade of 67,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 45,000 | 204,267 (0%) | 0% | 0 | Common Stock | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.89 per share. | 13 Feb 2026 | 5,134 | 159,267 (0%) | 0% | 11.9 | 61,043 | Common Stock |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.61 per share. | 24 Jun 2025 | 5,700 | 164,401 (0%) | 0% | 7.6 | 43,377 | Common Stock |
| Milestone Pharma Inc | Andrew R. Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 59,600 | 170,101 (0%) | 0% | 0 | Common Stock | |
| Arvinas Inc | Andrew Saik R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 74,960 | 74,960 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 49,092 | 110,501 (0%) | 0% | 0 | Common Stock | |
| Milestone Pharma Inc | Andrew Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Milestone Pharma Inc | Andrew Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 94,418 | 94,418 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 61,409 | 61,409 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.74 per share. | 21 Jun 2023 | 908 | 69,173 (0%) | 0% | 11.7 | 10,660 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.19 per share. | 21 Mar 2023 | 909 | 70,081 (0%) | 0% | 14.2 | 12,899 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 24,000 | 24,000 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 14,700 | 70,990 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.37 per share. | 31 Dec 2022 | 718 | 56,290 (0%) | 0% | 12.4 | 8,882 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.43 per share. | 21 Dec 2022 | 908 | 57,008 (0%) | 0% | 13.4 | 12,194 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.85 per share. | 21 Sep 2022 | 908 | 57,916 (0%) | 0% | 14.9 | 13,484 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.48 per share. | 21 Jun 2022 | 3,632 | 58,824 (0%) | 0% | 12.5 | 45,327 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 17,600 | 17,600 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 10,300 | 62,456 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.36 per share. | 28 May 2021 | 3,017 | 116,468 (0%) | 0% | 3.4 | 10,130 | Common Stock |